Search

Your search keyword '"Hans Wedel"' showing total 280 results

Search Constraints

Start Over You searched for: Author "Hans Wedel" Remove constraint Author: "Hans Wedel"
280 results on '"Hans Wedel"'

Search Results

51. An economic evaluation of rosuvastatin treatment in systolic heart failure

52. Plasma Concentration of Amino-Terminal Pro-Brain Natriuretic Peptide in Chronic Heart Failure: Prediction of Cardiovascular Events and Interaction With the Effects of Rosuvastatin

53. Baseline Heart Rate, Antihypertensive Treatment, and Prevention of Cardiovascular Outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial)

54. Hazard Function and Secular Trends in the Risk of Recurrent Acute Myocardial Infarction

55. The Influence of Renal Function on Clinical Outcome and Response to β-Blockade in Systolic Heart Failure: Insights From Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF)

56. Tolerability to Treatment with Metoprolol in Acute Myocardial Infarction in Relation to Age

57. Coffee Consumption and Coronary Heart Disease in Middle-aged Swedish Men

58. DEATHS AND NON-FATAL REINFARCTIONS DURING TWO YEARS‘ FOLLOW-UP

59. Separate and Combined Effects of Smoking and Alcohol Abuse in Middle-aged Men

60. Cause of Death in Relation to Social and Alcoholic Problems among Swedish Men Aged 35-44 Years

61. Influence of a Myocardial Infarction on Blood Pressure and Serum Cholesterol

62. Hypertensive Eye Ground Changes

63. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study

64. Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide

65. Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: The Losartan Intervention For End point reduction in hypertension (LIFE) study

66. The Lifetime Cost Effectiveness of Amlodipine-Based Therapy Plus Atorvastatin Compared with Atenolol Plus Atorvastatin, Amlodipine-Based Therapy Alone and Atenolol-Based Therapy Alone

67. Determinants of New-Onset Diabetes Among 19,257 Hypertensive Patients Randomized in the Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm and the Relative Influence of Antihypertensive Medication

68. Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects

69. Excess Mortality among Persons with Type 2 Diabetes

70. Prognostic Impact of Chronic Total Occlusions: A Report From SCAAR (Swedish Coronary Angiography and Angioplasty Registry)

71. Loop diuretics, renal function and clinical outcome in patients with heart failure and reduced ejection fraction

72. Economic Implications of Extended-Release Metoprolol Succinate for Heart Failure in the MERIT-HF Trial: A US Perspective of the MERIT-HF Trial

73. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics

74. Different Time Course for Prevention of Coronary and Stroke Events by Atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA)

75. The Effect of Losartan Versus Atenolol on Cardiovascular Morbidity and Mortality in Patients With Hypertension Taking Aspirin

76. Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors

77. Reduction in Cardiovascular Events With Atorvastatin in 2,532 Patients With Type 2 Diabetes

78. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity

79. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA)

80. Cost-Effectiveness of Atorvastatin for the Prevention of Coronary and Stroke Events: An Economic Analysis of the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA)

81. Can the relation between tooth loss and chronic disease be explained by socio-economic status? A 24-year follow-up from the Population Study of Women in Gothenburg, Sweden

82. What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker?

83. Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery

84. Lasting impact on health-related quality of life after a first myocardial infarction

85. Lipoprotein Changes and Reduction in the Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin Survival Study (4S)

86. Clinical trials: a summary

87. The impact of serum uric acid on cardiovascular outcomes in the LIFE study

88. Birth weight and cardiovascular risk factors in a cohort followed until 80 years of age: the study of men born in 1913

89. How Should Subgroup Analyses Affect Clinical Practice? Insights from the Metoprolol Succinate Controlled-Release/Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF)

90. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project

91. Benefits and risks of more intensive blood pressure lowering in hypertensive patients of the HOT study with different risk profiles

92. [Untitled]

93. Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk

94. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

95. Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure

96. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

97. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

98. ASSOCIATION BETWEEN HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE AND SURVIVAL IN DIABETIC PATIENTS WITH ACUTE CORONARY SYNDROMES: INSIGHTS FROM THE ALECARDIO TRIAL

99. The impact of coronary artery disease risk loci on ischemic heart failure severity and prognosis

100. Glycemic control and excess mortality in type 1 diabetes

Catalog

Books, media, physical & digital resources